Clinical Report: Trends and Challenges in Nitrosamine Testing: Part One

Overview

The detection of nitrosamines, particularly N-nitrosodimethylamine (NDMA), in pharmaceuticals has raised significant concerns regarding their carcinogenic potential, particularly following their detection in widely used medications like valsartan. This report outlines the historical context, analytical challenges, and regulatory responses to nitrosamine impurities in medications.

Background

Nitrosamines have gained attention due to their classification as probable human carcinogens, particularly following their detection in widely used medications like valsartan. The presence of these impurities has prompted global regulatory scrutiny.

Data Highlights

No numerical data available in the source material.

Key Findings

• Nitrosamines, including NDMA, were first detected in valsartan, leading to a global investigation.
• Not all nitrosamines carry the same level of risk; for example, NDEA has a lower acceptable intake limit due to its potency.
• Regulatory bodies like the EMA and FDA have issued guidelines for testing and controlling nitrosamine impurities in pharmaceuticals.
• Analytical methods for detecting nitrosamines are evolving, with LC-MS being a preferred technique for low-level quantitation.
• Environmental factors and interactions between active pharmaceutical ingredients (APIs) and excipients can facilitate nitrosamine formation.

Clinical Implications

Healthcare professionals should be aware of the potential risks associated with nitrosamine impurities in medications and the importance of regulatory compliance in testing and monitoring these compounds.

Conclusion

The ongoing challenges posed by nitrosamines in pharmaceuticals highlight the need for rigorous testing and regulatory oversight.

Related Resources & Content

1. FDA, Control of Nitrosamine Impurities in Human Drugs, 2024 -- Guidance Document
2. FDA, Determining Recommended Acceptable Intake Limits for N-nitrosamine Impurities in Pharmaceuticals, 2024 -- Guidance Document
3. The Medicine Maker, Trends and Challenges in Nitrosamine Testing: Part Two – Analytical Challenges, 2026 -- Article
4. The Medicine Maker, Trends and Challenges in Nitrosamine Testing: Part Five – Pharma’s Future, 2026 -- Article
5. The Medicine Maker, Trends and Challenges in Nitrosamine Testing Part Four – The Regulatory Landscape, 2026 -- Article
6. N‐nitrosodimethylamine‐Contaminated Valsartan and Risk of Cancer: A Nationwide Study of 1.4 Million Valsartan Users, PMC, 2024 -- Study
7. the medicine maker — Trends and Challenges in Nitrosamine Testing: Part Three – Building a Method
8. Control of Nitrosamine Impurities in Human Drugs | FDA
9. Determining Recommended Acceptable Intake Limits for N-nitrosamine Impurities in Pharmaceuticals: Development and Application of the Carcinogenic Potency Categorization Approach | FDA
10. N‐nitrosodimethylamine‐Contaminated Valsartan and Risk of Cancer: A Nationwide Study of 1.4 Million Valsartan Users - PMC